Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Oncology

Topics

Medicine

Internal Medicine

Surgery

Pulmonary And Respiratory Medicine

Radiation

Show all topics

DOI

10.1016/s1470-2045(16)30102-4

License

CC-BY

Other Formats

PDF